<DOC>
	<DOCNO>NCT00622479</DOCNO>
	<brief_summary>The purpose study : 1 . To elucidate mechanism involve sorafenib-induced hypophosphatemia possible early effect hypophosphatemia bone mineral density 2 . A secondary objective ass effect sorafenib treatment evaluate leave ventricular function ( LVEF ) Beta-type natriuretic peptide plasma .</brief_summary>
	<brief_title>Mechanistic Evaluation Sorafenib Induced Hypophosphatemia .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Hypophosphatemia</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Age &gt; /= 18 year Histologically cytologically confirm advanced RCC Evaluable disease lesion measure CTscan MRI accord modify Response Evaluation Criteria Solid Tumors ( RECIST ) ECOG Performance Status 0 1 Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dL 1 . Age great Than 18 yr old Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count 100,000/mm3 Total bilirubin &lt; = 1.5 time upper limit normal ALT AST &lt; = 2.5 x upper limit normal ( &lt; = 5 x upper limit normal patient liver involvement cancer ) Amylase lipase &lt; 1.5 x upper limit normal PTINR/PTT 1.5 x ULN ( Patients prophylactically anticoagulated agent coumadin low molecular weight heparin therapeutically anticoagulated LMWH allow participate provide meet criterion ; addition , patient must monitor appropriate interval throughout study ) Serum creatinine &lt; 2.0 x upper limit normal creatinine clearance ( CrCl ) 45 mL/min ( CrCl = Wt ( kg ) ( 140age ) /72 Cr level , female 0.85 ) patient creatinine level 2.0 x ULN Phosphate 2.0 mg/dl LVEF &gt; /= 40 % Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment . Negative result must available prior study treatment Women childbearing potential men must agree use adequate contraception prior study entry duration study participation , include 30 day period last study drug dosing . The investigator advise patient achieve adequate contraception Signed informed consent must obtain prior study specific procedure Patients meet follow criterion time screen exclude : History cardiac disease : congestive heart failure &gt; NYHA Class 2 ; hospitalization CHF symptoms 6 month prior study entry ; active CAD ( MI 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension Known history HIV infection chronic hepatitis B C Uncontrolled hypertension define systolic blood pressure &gt; 150 mmHg diastolic pressure &gt; 90 mmHg , despite optimal medical management Active clinically serious infection ( &gt; Grade 2 CTCAE v3 ) Known history presence metastatic brain meningeal tumor ( head CT MRI screen confirm ) Patients seizure disorder require medication ( steroids anti epileptic ) History organ allograft Patients undergoing renal dialysis Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry Anticancer chemotherapy immunotherapy study within 4 week study entry . Mitomycin C nitrosureas give within 6 week study entry . Anticancer therapy define agent combination agent clinically proven anticancer activity administer route purpose affect cancer , either directly indirectly , include palliative therapeutic endpoint Radiotherapy target lesion within 4 week start study drug Major surgery within 4 week start study Serious , nonhealing wound , ulcer , bone fracture Investigational drug therapy within 4 week study entry Prior exposure sorafenib Pregnant breastfeeding patient Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Any condition unstable could jeopardize safety patient compliance study Unable swallow oral medication Any malabsorption condition Current treatment bisphosphonates therapy prior therapy agent within 12 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Hypophosphatemia</keyword>
	<keyword>Left ventricular ejection fraction ( LVEF )</keyword>
	<keyword>Beta-type Natriuretic Peptide ( BNP )</keyword>
</DOC>